PARP: NOVEL THERAPEUTIC TARGET TO TREAT CANCER AND INFLAMMATORY DISEASES
Ritchu Sethi* and Sandeep Jain
ABSTRACT
Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes,
which show differences in structure, cellular location and functions.
However, all these enzymes possess poly (ADP-ribosyl)ation activity.
Overactivation of PARP enzymes has been implicated in the
pathogenesis of several diseases, including stroke, myocardial
infarction, diabetes, shock, neurodegenerative disorder and allergy.
Inhibitors of PARP-1 activity in combination with DNA-binding
antitumor drugs may constitute a suitable strategy in cancer
chemotherapy. In addition, PARP inhibitors may be also useful to
restore cellular functions in several pathophysiological states and
diseases. This review gives an update of the concerning PARP enzyme
and their exploitation as pharmacological targets in several illnesses.
Keywords: PARP; PARP inhibitors,cancer, inflammation.
[Download Article]
[Download Certifiate]